# Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia

> **NCT00004878** · PHASE2 · WITHDRAWN · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Graft Versus Host Disease
- Leukemia

## Interventions

- **BIOLOGICAL:** therapeutic allogeneic lymphocytes
- **DRUG:** cytarabine
- **DRUG:** fludarabine phosphate
- **DRUG:** idarubicin
- **DRUG:** methotrexate
- **DRUG:** tacrolimus
- **PROCEDURE:** in vitro-treated peripheral blood stem cell transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00004878
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study never opened
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004878, "Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00004878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*